Edition:
United Kingdom

Achaogen Inc (AKAO.OQ)

AKAO.OQ on NASDAQ Stock Exchange Global Market

0.50USD
8:00pm GMT
Change (% chg)

$-0.01 (-2.91%)
Prev Close
$0.51
Open
$0.53
Day's High
$0.54
Day's Low
$0.48
Volume
280,754
Avg. Vol
291,458
52-wk High
$15.00
52-wk Low
$0.48

Latest Key Developments (Source: Significant Developments)

Robert W. Duggan & Affiliates Report 11.1 Pct Stake In Achaogen Inc As Of March 11 - SEC Filing
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Robert W. Duggan: :ROBERT W. DUGGAN & AFFILIATES REPORT 11.1 PERCENT STAKE IN ACHAOGEN INC AS OF MARCH 11; PREVIOUSLY HAD REPORTED A 14.9 PERCENT STAKE AS OF FEB 25 - SEC FILING.  Full Article

Achaogen Inc Files For Non-Timely 10-K With U.S. SEC
Wednesday, 13 Mar 2019 

March 13 (Reuters) - Achaogen Inc ::ACHAOGEN INC FILES FOR NON-TIMELY 10-K WITH U.S. SEC.ACHAOGEN - IS UNABLE TO TIMELY FILE FORM 10-K DUE TO CO FOCUSING RESOURCES ON STRATEGIC REVIEW PROCESS.  Full Article

Achaogen Inc - On February 28, Commenced A Restructuring Of Its Organization
Wednesday, 6 Mar 2019 

March 6 (Reuters) - Achaogen Inc ::ACHAOGEN INC - ON FEBRUARY 28, COMMENCED A RESTRUCTURING OF ITS ORGANIZATION.ACHAOGEN INC - ESTIMATES IT WILL INCUR RESTRUCTURING CHARGES OF APPROXIMATELY $4.2 MILLION IN Q1 OF 2019.ACHAOGEN INC - RESTRUCTURING EXPECTED TO BE COMPLETE BY END OF Q2 OF 2019.ACHAOGEN INC - BY END OF Q2 EXPECTS TO HAVE ABOUT 40 FULL-TIME EMPLOYEES, OF WHICH ABOUT 25% EXPECTED TO BE COMMERCIAL AND MEDICAL AFFAIRS PERSONNEL.ACHAOGEN - ESTIMATES ONGOING QUARTERLY CASH OPERATING EXPENSES OF ABOUT $15 MILLION TO $17 MILLION FOLLOWING COMPLETION OF RESTRUCTURING CHARGES.ACHAOGEN - BELIEVES IT HAS SUFFICIENT CASH AND CASH EQUIVALENTS TO SUPPORT CURRENT PLANNED OPERATIONS THROUGH ABOUT Q2 END.ACHAOGEN - COMMENCED RESTRUCTURING TO FOCUS CASH RESOURCES ON COMMERCIALIZING ZEMDRI(REG) PRIMARILY IN OUTPATIENT SETTING, CERTAIN KEY GEOGRAPHIES.ACHAOGEN - COMMENCED RESTRUCTURING TO FOCUS CASH RESOURCES ON REVIEWING STRATEGIC ALTERNATIVES.ACHAOGEN INC - MAJORITY OF ROLES ELIMINATED IN RESTRUCTURING ARE FIELD-BASED SALES AND MEDICAL SCIENTIST POSITIONS.ACHAOGEN INC - ABOUT 59% OF RESTRUCTURING CHARGES IS EXPECTED TO RESULT IN CASH EXPENDITURES.  Full Article

Achaogen Announces Proposed Public Offering Of Common Stock
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Achaogen Inc ::ACHAOGEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ACHAOGEN INC - EXPECTS TO USE NET PROCEEDS FROM THIS OFFERING TO FUND COMMERCIALIZATION OF ZEMDRI IN UNITED STATES.  Full Article

Robert Duggan Says Raises Stake In Achaogen To 20.4 Pct
Wednesday, 12 Dec 2018 

Dec 12 (Reuters) - Achaogen Inc ::ROBERT DUGGAN SAYS INCREASES STAKE IN ACHAOGEN INC TO 20.4 PERCENT AS OF DECEMBER 3 FROM A STAKE OF 18.4 PERCENT AS OF MAY 3 - SEC FILING.  Full Article

Achaogen Reports Q2 Loss Per Share Of $1.20
Monday, 6 Aug 2018 

Aug 6 (Reuters) - Achaogen Inc ::ACHAOGEN REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $1.20.Q2 EARNINGS PER SHARE VIEW $-0.92 -- THOMSON REUTERS I/B/E/S.QTRLY CONTRACT REVENUE $2.6 MILLION VERSUS $1.3 MILLION.ACHAOGEN - AT JUNE 30, 2018, HAD $100.5 MILLION IN UNRESTRICTED CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS COMPARED TO $164.8 MILLION AT DEC 31, 2017.  Full Article

Achaogen Announces Strategic Update
Thursday, 26 Jul 2018 

July 26 (Reuters) - Achaogen Inc ::ACHAOGEN ANNOUNCES STRATEGIC UPDATE TO ALIGN OPERATIONS WITH COMMERCIAL AND CLINICAL DEVELOPMENT PRIORITIES.ACHAOGEN INC - - COMMERCIAL AND MEDICAL AFFAIRS TEAMS UNCHANGED BY RESTRUCTURING AS COMPANY EXECUTES ON U.S. COMMERCIAL LAUNCH OF ZEMDRI.ACHAOGEN - ESTIMATES RESTRUCTURING WILL RESULT IN ELIMINATION OF ABOUT 80 POSITIONS, OR ABOUT 28 PERCENT, OF CO'S WORKFORCE.ACHAOGEN INC - ESTIMATES ONE-TIME EMPLOYEE SEVERANCE AND BENEFITS CHARGE OF APPROXIMATELY $6.0M IN Q3 OF 2018.ACHAOGEN INC - COMPANY WILL ALSO RESTRUCTURE ACHAOGEN EXECUTIVE MANAGEMENT TEAM.ACHAOGEN INC - ZERYN SARPANGAL WILL ASSUME ROLE OF CHIEF FINANCIAL OFFICER ON OCTOBER 1, 2018.  Full Article

Achaogen Says Zemdritm Approved By FDA For Treatment Of Adults With Complicated Urinary Tract Infections
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Achaogen Inc ::ZEMDRITM (PLAZOMICIN) APPROVED BY FDA FOR THE TREATMENT OF ADULTS WITH COMPLICATED URINARY TRACT INFECTIONS (CUTI).ACHAOGEN INC - REGARDING POTENTIAL INDICATION FOR PLAZOMICIN FOR TREATMENT OF BLOODSTREAM INFECTION (BSI), FDA ISSUED A COMPLETE RESPONSE LETTER.ACHAOGEN INC - CRL STATES THAT CARE STUDY DOES NOT PROVIDE SUBSTANTIAL EVIDENCE OF EFFECTIVENESS OF PLAZOMICIN FOR TREATMENT OF BSI.ACHAOGEN INC - INTENDS TO MEET WITH FDA TO DETERMINE WHETHER THERE IS A FEASIBLE RESOLUTION TO ADDRESS CRL.  Full Article

Achaogen Announces FDA Acceptance Of New Drug Application With Priority Review For Plazomicin
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Achaogen Inc ::ACHAOGEN ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION WITH PRIORITY REVIEW FOR PLAZOMICIN FOR TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND BLOODSTREAM INFECTIONS.ACHAOGEN - INTENDS TO SUBMIT APPLICATION FOR MARKETING AUTHORIZATION FOR PLAZOMICIN IN EUROPEAN UNION IN 2018.  Full Article

Achaogen Announces Positive Top-Line Results From First Clinical Trial Of Orally-Administered Antibacterial Candidate C-Scape
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Achaogen Inc ::ACHAOGEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM FIRST CLINICAL TRIAL OF ORALLY-ADMINISTERED ANTIBACTERIAL CANDIDATE C-SCAPE.ACHAOGEN INC - C-SCAPE WAS WELL TOLERATED ACROSS ALL DOSES STUDIED IN PHASE 1 TRIAL.ACHAOGEN INC - CONTINUE TO PLAN FOR PHASE 3 IN 2018.  Full Article